Aclarion Highlights Accelerating Growth, $13.3M Cash Balance, And AI-Driven Biomarker Validation Progress
Benzinga Newsdesk 1 year ago
News
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growthNociscan scan volumes increase +89% year-over-year with third
- Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth
- Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets
- CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues